Outpatient treatment with AZD7442 (tixagevimab/cilgavimab) prevented Covid-19 hospitalizations over 6 months and reduced symptom progression in the TACKLE randomized trial by Hobbs, FDR, Montgomery, H, Padilla, F, Simón-Campos, JA, Kim, K, Arbetter, D, Padilla, KW, Reddy, VP, Seegobin, S, Streicher, K, Templeton, A, Viani, RM, Johnsson, E, Koh, GCKW, Esser, MT

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-cont... by Montgomery, H, Hobbs, FDR, Padilla, F, Arbetter, D, Templeton, A, Seegobin, S, Kim, K, Campos, JAS, Arends, RH, Brodek, BH, Brooks, D, Garbes, P, Jimenez, J, Koh, GCKW, Padilla, KW, Streicher, K, Viani, RM, Alagappan, V, Pangalos, MN, Esser, MT, TACKLE Study Group